Cemiplimab + Fianlimab for Nasopharyngeal Cancer

This trial tests new cancer treatments for individuals with advanced nasopharyngeal carcinoma, a cancer located in the upper part of the throat behind the nose. Researchers aim to determine if cemiplimab, an immunotherapy drug, used alone or with another immunotherapy drug called fianlimab, is effective alongside standard chemotherapy drugs in combating this cancer. The trial includes two groups: one receiving cemiplimab alone and the other receiving both cemiplimab and fianlimab. Individuals diagnosed with this specific type of nasopharyngeal cancer who have not undergone prior head or neck radiation may be suitable candidates. As a Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive this new therapy.

Research has shown that patients generally tolerate the combination of cemiplimab and fianlimab well. In one study, 87% of patients reported side effects during treatment, ranging from mild to severe. About 44% experienced more serious side effects, classified as grade 3 or higher.

Most treatments for nasopharyngeal cancer typically involve chemotherapy, radiation, or targeted therapies like cetuximab. However, cemiplimab and fianlimab are unique because they are immune checkpoint inhibitors. These drugs work by targeting proteins that usually help cancer evade the immune system, allowing the body to attack the cancer more effectively. Researchers are excited about these treatments because they offer a new way to harness the immune system against cancer, potentially leading to better outcomes for patients with nasopharyngeal cancer.

This trial will evaluate the effectiveness of cemiplimab alone and in combination with fianlimab for nasopharyngeal cancer. Research has shown that this combination holds promise for treating certain cancers. In earlier studies, about 61% of patients who received this combination experienced significant tumor shrinkage. Additionally, some patients went about 15 months without their cancer worsening. This combination has also succeeded in treating melanoma, suggesting potential effectiveness for other cancers like nasopharyngeal carcinoma. These findings indicate that the treatment could be effective against advanced nasopharyngeal cancer, but further research is needed to confirm this.¹²³⁴⁶